VBI-1901 is under clinical development by VBI Vaccines and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect VBI-1901’s likelihood of approval (LoA) and phase transition for Recurrent Glioblastoma Multiforme (GBM) took place on 20 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their VBI-1901 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

VBI-1901 overview

VBI-1901 is under development for the treatment of recurrent glioblastoma multiforme and medulloblastoma. It is administered intradermally when adjuvanted with GM-CSF and intramuscularly when adjuvanted with the AS01B adjuvant system. The vaccine candidate constitutes a virus-like particle expressing two CMV antigens, glycoprotein B, and pp65. It is developed based on eVLP virus-like particle (VLP) vaccine technology.

VBI Vaccines overview

VBI Vaccines (VBI), a subsidiary of FDS Pharma LLP is a biopharmaceutical company that discovers and develops novel vaccines in the therapeutic areas of immuno-oncology and infectious diseases. The company’s pipeline vaccine candidates include cytomegalovirus; glioblastoma multiforme, and zika virus. It utilizes technologies such as eVLP platform, and thermostable platform to develop the vaccine candidates. VBI offers Sci-B-Vac, a hepatitis B vaccine which consists of surface antigens of hepatitis B virus and is free of any next-generation adjuvant. The company operates through its research facilities located in Ottawa, Canada; and a manufacturing facility in Rehovot, Israel. VBI is headquartered in Cambridge, Massachusetts, the US.

Quick View VBI-1901 LOA Data

Report Segments
  • Innovator
Drug Name
  • VBI-1901
Administration Pathway
  • Intradermal
  • Intramuscular
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.